Skip to main content

PEEL-224 in Solid Tumors

PEEL-224 in Solid Tumors

Contact

If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is now recruiting. Learn more about enrolling here.

Description

This study enrolls patients with refractory, progressive, or relapsed solid tumors. The purpose of this study is to find out whether a drug called PEEL-224 ("the study drug") is safe and effective when given as monotherapy (a drug given by itself) and as part of a combination therapy together with other chemotherapy drugs.

What to expect

Participants in the research will:

  • Receive PEEL-224 infusions, either by itself or in combination with other chemotherapy drugs
  • Complete frequent clinic visits at CHOP Philadelphia campus
  • Have frequent blood tests
  • Have periodic imaging performed as part of regular cancer care to evaluate the response to treatment
  • Have research genetic tests (if not previously done clinically)
  • Submit leftover tissue samples to the study repository
  • Complete questionnaires
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Jump back to top